Evaluate every Ozempic and GLP-1 claim against the evidence that determines case strength.

The GLP-1 mass tort involves claims that manufacturers of GLP-1 receptor agonist medications, including Ozempic, Wegovy, Mounjaro, Trulicity, and others, failed to adequately warn patients and physicians about severe and sometimes permanent side effects. The central theory is failure to warn: that manufacturers knew their drugs' gastric-slowing mechanism could cause serious gastrointestinal and ocular injuries but concealed or minimized that risk in their labeling.

The litigation has two active injury tracks. The GI track covers Gastroparesis, Ileus, and intestinal obstruction, along with additional injuries including Pancreatitis, Gallbladder Disease, Bowel Ischemia, Thiamine Deficiency, and Acute Kidney Injury. The ocular track covers NAION, or Non-Arteritic Anterior Ischemic Optic Neuropathy, a sudden and often permanent form of vision loss sometimes referred to as an eye stroke. Pattern's Lens is built for both tracks.

Following Judge Marston's August 2025 ruling, Gastroparesis claims must be supported by objective diagnostic testing, specifically a gastric emptying study. Claims that have a Gastroparesis diagnosis in the medical records but no gastric emptying study on file are materially at risk. Pattern identifies exactly which claimants have the required documentation and which have a gap that needs to be closed before bellwether selection.

Manufacturers are expected to argue that claimants who used compounded, non-brand name GLP-1 formulations are outside their control and responsibility. This is a case-level disqualifier. Pattern automatically flags compounded use across the entire inventory, giving firms immediate visibility into the risk their dockets may be carrying without structured data capture for it.

Pattern assigns every claimant a Development Case Score on a 0 to 6 scale, calculated from exposure type, injury classification, use duration, hospitalization evidence, and related surgery or death. This gives firms a litigation-independent case strength signal they can use today, before global settlement criteria are announced, to triage their docket and focus development resources where they matter most.

Most firms have structured their intake around the GI track. The NAION vision loss track was established as a separate federal track in late 2025 and is now moving at an accelerated pace. Pattern's Lens captures both tracks from the initial build, so firms are not undercounting their NAION exposure or missing a growing claim category that the broader market has been slow to recognize.

Pattern structures medical history to surface information that is likely to be relevant to causation arguments, including diabetes history and A1C levels, prior GI surgeries, and smoking and alcohol history. Capturing this data early gives firms a more complete picture of each case before committing development resources, rather than encountering it later as a surprise.